Investment Rating - The report indicates a positive outlook on the Chinese innovative drug industry chain, with a focus on business development (BD), policy, and clinical advancements [1]. Core Insights - The innovative drug BD authorization total exceeded $60 billion in Q1 2026, reflecting accelerated global cooperation value [2][11]. - The Chinese government has upgraded its strategic positioning of the biopharmaceutical industry, marking it as a "new emerging pillar industry" in the 2026 government work report [2][15]. - Clinical activity is on the rise, with Chinese innovative drug R&D entering a high-quality harvest period, as evidenced by a significant increase in the number of innovative drugs entering clinical trials and being approved for market [2][16][19]. Market Observation - The pharmaceutical and biotechnology sector rose by 1.56% this week, ranking 4th out of 31 sectors, while it has seen a year-to-date decline of 1.38%, ranking 17th [1][10]. Industry Dynamics - In 2025, the total transaction amount for Chinese innovative drug BD reached a historical high of $135.655 billion, with 157 transactions, and the first quarter of 2026 has already seen over $60 billion in transactions [2][11]. - The first version of the commercial health insurance innovative drug catalog was officially launched, enhancing the multi-layered payment system for innovative drugs [2][15]. - By the end of 2025, China accounted for 33.7% of the global innovative drugs in development, leading the world, with 827 innovative drugs entering clinical trials for the first time [2][16][19]. Company Dynamics - **Insilico Medicine**: Announced a collaboration with Eli Lilly, with an upfront payment of $115 million and a total deal value of up to $2.75 billion, validating the commercial potential of its AI drug development platform [3][23]. - **Kangfang Biopharma**: Achieved revenue of 3.056 billion yuan in 2025, a year-on-year increase of 43.9%, driven by core dual-antibody products [3][24]. - **Innovent Biologics**: Reported total revenue of 13.042 billion yuan in 2025, a 38.4% increase, marking its first year of profitability with a significant growth in product revenue [3][25]. - **Kolin Biotech**: Generated revenue of 2.058 billion yuan in 2025, with a focus on the commercialization of its core ADC products [3][26]. - **Ascletis Pharma**: Achieved record revenue of 7.731 billion yuan in 2025, with innovative drugs accounting for 81.5% of total revenue [3][27]. - **Zai Lab**: Reported revenue of 269.6 million yuan in 2025, with a strong cash reserve of 919 million yuan, supporting its global expansion plans [3][28].

Summary of the Conference Call for Kangfang Biopharma Company Overview - **Company**: Kangfang Biopharma - **Date**: March 27, 2026 Key Industry and Company Insights 1. Product and Market Access Achievements - In 2025, all five products of Kangfang Biopharma, covering 12 indications, were successfully included in the national medical insurance directory, significantly supporting sales growth in 2026 [2][5] - The commercial revenue for 2025 reached 3.033 billion yuan, marking a 51% increase year-on-year, primarily driven by two dual-antibody products [3][29] - The company expanded its commercial team to 1,500 people, doubling from approximately 800 in 2024, and achieved a 90% hospital access rate for its dual-antibody products [3][4] 2. Clinical Development and Product Pipeline - **Ivosidenib (PD-1/VEGF)**: Currently involved in 15 global Phase III clinical trials, with significant results expected in 2026. It is the only PD-1/VEGF dual antibody approved in the U.S. and has benefited around 70,000 patients [6][12] - **Kadonil (PD-1/CTLA-4)**: Demonstrated significant overall survival (OS) advantages in PD-L1 negative populations and is undergoing Phase III trials for first-line gastric cancer [6][15][17] - **Immunology Products**: The first self-developed product, Inokizumab (IL-12/23), was approved in 2025 for psoriasis and included in the national insurance directory [8] 3. Financial Performance - Total revenue for 2025 was 3.056 billion yuan, with a cash reserve of 9 billion yuan, indicating a strong financial position [29] - R&D expenditure was 1.575 billion yuan, with a decreasing R&D intensity ratio from 78% in 2023 to 52% in 2025, aiming for a target of around 25% [29] - The adjusted EBITDA loss narrowed to 191 million yuan, compared to a loss of 241 million yuan in 2024, reflecting improved financial health [29] 4. Strategic Collaborations and Future Plans - The company has partnered with Jichuan Pharmaceutical for the commercialization of its PCSK9 antibody, optimizing sales efficiency through external collaboration [10] - Future product launches are planned, with expectations for ten new products and over 25 indications in the next five years [31] 5. Technological Advancements - The company is upgrading its technology platform to "IO 2.0 + ADC 2.0," focusing on combining dual antibodies with antibody-drug conjugates (ADCs) to lead the next generation of cancer immunotherapy [4][11] - AI technology is being integrated across various business operations to enhance efficiency and quality in drug development [30][32] 6. Clinical Milestones and Regulatory Progress - Significant clinical milestones were achieved in 2025, including positive results from the HARMONi-A and HARMONi-3 studies, which are expected to enhance the credibility of Chinese innovative drugs in international markets [13][14] - The company is actively preparing for further international clinical trials and regulatory submissions, particularly for Ivosidenib and Kadonil in various indications [33][34] Additional Important Insights - The dual-antibody products are positioned as foundational therapies for future cancer treatment paradigms, with ongoing studies exploring their combination with ADCs and other novel therapies [19][28] - The company is also exploring innovative treatments in autoimmune diseases and central nervous system disorders, leveraging its dual-target antibody platform [21][22] This summary encapsulates the key points from the conference call, highlighting the company's achievements, strategic direction, and future outlook in the biopharmaceutical industry.

Investment Rating - The report maintains a positive outlook on the Chinese innovative drug industry chain, highlighting the potential for growth driven by business development (BD), policy support, and clinical advancements [1]. Core Insights - The innovative drug BD authorization total exceeded $60 billion in Q1 2026, indicating accelerated realization of global collaboration value. In 2025, the total transaction amount for Chinese innovative drug BD reached a historical high of $135.655 billion, with 157 transactions [2][11]. - The government has upgraded its strategic positioning of the biopharmaceutical sector, now recognized as a "new emerging pillar industry" in the 2026 government work report. This includes the establishment of a multi-layered payment system for innovative drugs [2][15]. - Clinical activity is on the rise, with China leading globally in the number of innovative drugs under development, accounting for 33.7% of the total. By the end of 2025, 827 original innovative drugs entered clinical trials, representing 47.4% of the global total [2][16][19]. Market Observation - The pharmaceutical and biotechnology sector saw a weekly increase of 1.56%, ranking 4th out of 31 sectors, while year-to-date, the sector has declined by 1.38%, ranking 17th [1][10]. Company Dynamics - **Insilico Medicine**: Announced a collaboration with Eli Lilly, with an upfront payment of $115 million and a total deal value potentially reaching $2.75 billion, validating the commercial value of its AI drug development platform [3][23]. - **Kangfang Biopharma**: Reported a revenue of 3.056 billion yuan in 2025, a 43.9% increase year-on-year, driven by the commercialization of its core dual-antibody products [3][24]. - **Innovent Biologics**: Achieved a total revenue of 13.042 billion yuan in 2025, a 38.4% increase, marking its first time surpassing 10 billion yuan in revenue and returning to profitability [3][25]. - **Kolin Biotech**: Generated revenue of 2.058 billion yuan in 2025, a 6.5% increase, with its core ADC product contributing to its commercial growth [3][26]. - **Ascletis Pharma**: Reported a total revenue of 7.731 billion yuan in 2025, a 16.5% increase, with innovative drugs accounting for 81.5% of its revenue [3][27]. - **Zymeworks**: Achieved revenue of 269.6 million yuan in 2025, with a strong cash reserve of 919 million yuan, supporting its global expansion plans [3][28].

Industry Insights - The electrolytic aluminum industry faces heightened supply risks following the attack on EGA's Al Taweelah smelter in Abu Dhabi, which has suffered significant damage due to missile and drone strikes [2][6][7] - EGA's production capacity accounts for approximately 2% of global electrolytic aluminum supply by 2025, indicating a substantial impact on the market [7] - The attack is viewed as a planned action, suggesting that more smelting facilities in the Middle East could be at risk, further increasing supply-side concerns [7] Company Analysis - BYD's 4Q25 earnings fell short of expectations, with net profit down 18% compared to forecasts, attributed to a decrease in gross margin and lower financial income [8][9] - The company is expected to benefit from increased exports and energy storage solutions, projecting a sales volume of 5 million units in 2026, with 1.5 million units coming from exports [8][9] - BYD's revenue is anticipated to grow by 9% and 8% in 2026 and 2027, respectively, maintaining a gross margin of 17.8% [9] Company Analysis (Continued) - Great Wall Motors reported a 16% year-on-year revenue increase in 4Q25, reaching a record high, with core net profit aligning with expectations despite a slight decline in gross margin [10][11] - The new platform is expected to enhance pricing competitiveness, with an upward revision of sales expectations for the WEY brand to 200,000 units in 2026 [10][11] - The company anticipates a 19% increase in net profit for 2026, reaching 11.8 billion yuan, supported by export growth and product structure optimization [11] Company Analysis (Continued) - GAC Group's 4Q25 performance met profit warnings, with revenue up 22% year-on-year, although net losses were reported due to increased impairment losses [12][13] - The launch of the Qijun brand in collaboration with Huawei is expected to be a key catalyst for stock performance, alongside a target to double export volumes to 250,000 units by 2026 [12][13] - The company is projected to narrow net losses to 4.8 billion yuan in 2026, supported by cost reduction efforts [13] Company Analysis (Continued) - Innovent Biologics reported a strong 2025 performance with total revenue reaching 13 billion yuan, driven by new product launches [18][19] - The company is transitioning towards a fully integrated global biopharmaceutical company, with significant partnerships enhancing its development capabilities [19][20] - Key catalysts for 2026 include pivotal clinical data readouts for IBI363 and IBI343, which could significantly impact the company's valuation [20] Company Analysis (Continued) - Kangfang Biotech achieved a 52% increase in product sales in 2025, with expectations for further growth driven by new indications being added to the national insurance directory [22][23] - The company is focusing on global expansion for its key products, with pivotal trials underway for its lead assets [25][26] - Anticipated data readouts for IBI363 and IBI343 in 2026 are expected to be significant value drivers for the company [24][25] Company Analysis (Continued) - Xunfei Medical reported a 24.7% revenue increase in 2025, although growth was slower than expected in the G-end business [26][27] - The company is expanding its customer base significantly, with services now covering over 77,000 grassroots medical institutions [27][28] - The synergy between G-end and B-end businesses is expected to enhance long-term revenue growth resilience, with a shift towards more recurring revenue models [28][29] Company Analysis (Continued) - China Tower's FY25 revenue grew by 2.7% to 100.4 billion yuan, with net profit increasing by 8.4% [30][31] - The company experienced a decline in EBITDA due to increased bad debt provisions and reduced asset disposal gains [31] - A dividend payout of 0.458 yuan per share was announced, reflecting a payout ratio of 77% [31]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry [5] Core Viewpoints - Short-term fluctuations do not change the long-term growth trajectory of the innovative drug sector. Despite recent market volatility, the underlying logic for medium to long-term growth remains intact, driven by globalization, technological breakthroughs, and industry upgrades [8][12] - The focus has shifted from "can we go global" to "what progress has been made after going global," emphasizing the importance of overseas clinical deployment and milestone achievements for innovative drugs [13][14] - Breakthroughs in frontier technologies, particularly in small nucleic acids and CAR-T therapies, position Chinese companies to become core global assets [18][20] - The commercialization of innovative drugs is expected to lead to a profitability inflection point, with key companies entering a positive cycle of product volume growth and reinvestment in R&D [22] Summary by Sections 1. Short-term Fluctuations, Long-term Growth - The innovative drug sector has experienced significant volatility due to concentrated expectations and emotions, but the long-term growth trend remains unchanged [8][12] - The valuation of leading companies has reached reasonable levels, suggesting potential investment opportunities as market sentiment stabilizes [12] 1.1 Focus on Globalization Progress - The emphasis has shifted to the progress of products in overseas clinical trials, with a focus on key data readouts and milestone achievements [13][14] - Domestic bispecific antibodies are accelerating their global clinical trials, becoming core trading assets in the context of expiring patents for PD-(L)1 products [13] 1.2 Breakthroughs in Frontier Technologies - Chinese companies are leading in small nucleic acids and CAR-T therapies, with significant advancements in delivery technologies expanding treatment options beyond rare diseases [18] - In vivo CAR-T therapies have shown preliminary clinical effectiveness, with a growing number of transactions indicating a shift towards mainstream adoption [20] 1.3 Commercialization Driving Profitability - Leading innovative drug companies are entering a cycle of product volume growth that supports R&D reinvestment, with expectations for exceeding market performance in 2023 [22] - The upcoming earnings period in March-April 2026 is seen as a critical validation point for the sector [22] 2. Global New Drugs: Highlights in Autoimmunity and Oncology - The report highlights the approval of the world's first PD-L1/TGF-β bispecific antibody, showcasing the R&D capabilities of domestic companies [26][27] - The successful launch of innovative drugs in critical therapeutic areas reflects the growing strength of domestic pharmaceutical companies in addressing unmet medical needs [26][27]

Core Viewpoint - The introduction of a dual-track payment system for innovative drugs in China, combining basic medical insurance and commercial health insurance, marks a significant shift in the industry, providing a structured approach to address the payment challenges faced by high-priced innovative drugs [2][5][34]. Summary by Sections Introduction - The release of the new medical insurance directory and the first commercial health insurance directory for innovative drugs signifies the establishment of a dual-track payment system in China [2]. Innovative Drug Payment Mechanism - The reliance on a single payment channel through medical insurance has become unsustainable due to rising costs and the increasing number of high-priced innovative drugs [5]. - The latest medical insurance directory adds 114 new drugs, with 50 being class 1 innovative drugs, achieving a negotiation success rate of 88%, the highest ever [5]. Commercial Health Insurance Directory - The first commercial health insurance directory includes 19 high-value innovative drugs, providing a structured payment pathway for drugs previously excluded from medical insurance [8][20]. - This directory signals a shift in the payment structure, where both basic medical insurance and commercial insurance will share the payment responsibilities for innovative drugs [8][21]. Challenges in Medical Insurance - Despite the expansion of the medical insurance directory, high-priced innovative drugs still face significant barriers to entry due to strict cost-effectiveness evaluations and negotiation mechanisms [10][11]. - The trend indicates that medical insurance is moving towards risk control rather than merely expanding coverage [10][16]. Filling the Payment Gap - The introduction of the commercial health insurance directory is a necessary response to the limitations of the medical insurance system, providing a payment avenue for high-value drugs that have been excluded [18][21]. - The directory includes drugs with high clinical value and costs, addressing the long-standing payment vacuum in the market [18][20]. Growth Opportunities for Innovative Drugs - The commercial health insurance directory opens new growth avenues for high-priced innovative drugs, allowing for a broader patient reach and a more structured payment approach [23][24]. - The directory is expected to enhance the commercial health insurance market, with high-value innovative drugs becoming a core differentiator in product offerings [24]. Structural Bottlenecks for Commercial Health Insurance - There are significant barriers to the short-term adoption of the commercial health insurance directory, including data insufficiency, product risk acceptance, and user payment behavior [28][29][30]. - The lack of real-world data on innovative drug usage complicates pricing and risk assessment for insurance companies [29]. Conclusion - The dual-track payment system represents a structural change in the payment landscape for innovative drugs, but challenges remain in achieving widespread accessibility and effective implementation [34][35]. - The commercial health insurance system is expected to play an increasingly important role in providing payment solutions for innovative drugs, although it will take time to fully realize its potential [36].

Group 1 - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with the high-volatility Hong Kong Stock Connect innovative drug ETF (520880) rising over 1% after a four-day decline, indicating a potential end to this downward trend [1] - This week, the ETF has seen a significant inflow of "bottom-fishing" funds, with a cumulative net subscription amount exceeding 130 million yuan [1] - Leading stocks in the sector include Kangfang Biotech, which surged over 6.8%, and other notable gainers such as Innovent Biologics and BeiGene [3] Group 2 - Kangfang Biotech's PD-1/CTLA-4 dual-specific antibody, Kadcyla, has received FDA approval to conduct a Phase III clinical trial for treating HER2-negative, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma [3] - According to Ping An Securities, the rise of innovative drugs is sustainable from three perspectives: business development, commercialization, and policy [3] - The report suggests focusing on companies with rich pipelines, those with high potential single products, and firms leading in advanced technology platforms [3] Group 3 - The Hong Kong innovative drug sector has been in a correction phase since early September, with nearly three months of adjustment, enhancing the cost-effectiveness of investments [3] - The Hong Kong Stock Connect innovative drug ETF (520880) is the largest in its category, with a scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan since its inception [4] - The index tracked by the ETF has a significant concentration of leading stocks, with the top ten holdings accounting for over 72% of the total weight, indicating strong leadership in the innovative drug sector [4]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with the high-volatility Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 1%, potentially ending a four-day losing streak. Notably, this week has seen a net subscription of over 130 million yuan, indicating increased buying interest [1][6]. Group 1: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a cumulative net subscription of over 130 million yuan this week [1][6]. - As of November 30, the ETF's scale reached 2.142 billion yuan, with an average daily trading volume of 458 million yuan since its listing, making it the largest and most liquid among its peers [10]. Group 2: Sector Dynamics - The leading stock, Kangfang Biologics, surged over 6.8%, while other notable stocks like Innovent Biologics and BeiGene also saw gains of over 2% and 1%, respectively [8]. - Kangfang Biologics has received FDA approval to conduct a Phase III clinical trial for its PD-1/CTLA-4 dual-specific antibody, indicating significant advancements in innovative drug development [3][8]. Group 3: Investment Insights - A report from Ping An Securities suggests that the rise of innovative drugs is sustainable, recommending attention to companies with rich pipelines, high-potential single products, and leading technology platforms [3][8]. - The Hong Kong innovative drug sector has been in a correction phase since early September, enhancing the cost-effectiveness of investments in this area [3][8]. Group 4: Index Characteristics - The underlying index for the ETF, the Hang Seng Stock Connect Innovative Drug Select Index, has a significant concentration of leading stocks, with the top ten holdings accounting for over 72% of the index weight [4][9]. - The index is designed to exclude CXO companies, focusing solely on innovative drug developers, which enhances its purity and comprehensiveness [9].

Core Viewpoint - Kangfang Biopharma (09926) has seen a stock increase of over 3%, currently at 121.9 HKD, with a trading volume of 271 million HKD, following the announcement of FDA approval for its innovative PD-1/CTLA-4 bispecific antibody, Cadonilimab, for a Phase III clinical trial [1] Group 1 - The FDA has approved the international multicenter Phase III clinical study (COMPASSION-37/AK104-311) for Cadonilimab in combination with chemotherapy for HER2-negative, untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [1] - COMPASSION-37 is the second international multicenter registration clinical study for Cadonilimab, following a previous study for immune-resistant hepatocellular carcinoma that has already commenced in the U.S. [1] - The initiation of the COMPASSION-37 study marks a significant step forward in the global development of Cadonilimab and is a key initiative in Kangfang Biopharma's globalization strategy, reinforcing its international leadership in the field of tumor immunotherapy 2.0 [1]

Core Viewpoint - 康方生物's stock has increased by over 3%, currently trading at 121.9 HKD with a transaction volume of 271 million HKD, following the announcement of FDA approval for its innovative PD-1/CTLA-4 bispecific antibody, 卡度尼利单抗, for a pivotal clinical trial [1] Group 1: Company Developments - 康方生物 announced the initiation of the COMPASSION-37/AK104-311 international multicenter phase III clinical study, which evaluates 卡度尼利单抗 in combination with chemotherapy for HER2-negative, untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [1] - This study represents the second international multicenter registration clinical trial for 卡度尼利, following a previous study focused on immune-resistant hepatocellular carcinoma that has already commenced in the United States [1] - The launch of the COMPASSION-37 study is a significant step forward in the global development of 卡度尼利 and is a key initiative in 康方生物's globalization strategy, reinforcing its leading position in the field of tumor immunotherapy 2.0 [1]